X4 Pharmaceuticals, Inc. (XFOR) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.88
↓-64% vs avg
5yr avg: 2.45
30Y Low0.1·High6.7
ROE
↑
-76.0%
↓+37% vs avg
5yr avg: -121.0%
30Y Low-162%·High-62%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
XFOR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
X4 Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $490M | $169M | $148M | $149M | $63M | $59M | $129M | $123M | $1M | $4M | — |
| Enterprise Value | $350M | $29M | $170M | $108M | $-20216692 | $17M | $89M | $20M | $3M | $-60172409 | — |
| P/E Ratio → | -2.07 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 13.96 | 4.82 | 57.69 | — | — | — | 43.03 | — | — | — | — |
| P/B Ratio | 0.88 | 0.91 | 6.66 | 2.92 | 0.85 | 0.92 | 1.77 | 0.95 | — | 0.07 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
XFOR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | 66.44 | — | — | — | 29.52 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
XFOR Profitability
Margins and return-on-capital ratios measuring operating efficiency
X4 Pharmaceuticals, Inc. earns an operating margin of -247.4%. Operating margins have expanded from -1423.6% to -247.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -76.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.2% | 82.2% | 68.8% | — | — | — | 59.0% | — | — | — | — |
| Operating Margin | -247.4% | -247.4% | -1423.6% | — | — | — | -1995.8% | — | — | — | — |
| Net Profit Margin | -225.6% | -225.6% | -1464.6% | — | — | — | -2071.0% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -76.0% | -76.0% | -102.3% | -161.7% | -135.6% | -129.3% | -61.5% | -89.9% | -141.5% | -161.4% | — |
| ROA | -36.3% | -36.3% | -25.5% | -66.8% | -68.8% | -73.9% | -43.8% | -61.9% | -73.0% | -76.2% | -268.5% |
| ROIC | -143.1% | -143.1% | -99.8% | -17588.1% | -997.9% | -206.7% | -154.3% | -439.6% | — | — | — |
| ROCE | -45.9% | -45.9% | -30.6% | -83.5% | -74.1% | -70.4% | -45.7% | -61.1% | -80.1% | -109.3% | — |
XFOR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $217M exceeds total debt of $77M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 3.53 | 1.14 | 0.52 | 0.62 | 0.53 | 0.18 | — | 0.21 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.75 | 1.01 | -0.80 | -1.12 | -0.65 | -0.56 | -0.80 | — | -1.10 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -9.79 | -9.79 | -3.24 | -16.50 | -22.50 | -20.69 | -22.27 | -21.80 | -40.40 | -17.38 | -9.68 |
Net cash position: cash ($217M) exceeds total debt ($77M)
XFOR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
X4 Pharmaceuticals, Inc.'s current ratio of 10.16x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.34x to 10.16x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.16 | 10.16 | 3.41 | 5.34 | 5.76 | 6.27 | 6.97 | 13.68 | 1.18 | 7.45 | 0.47 |
| Quick Ratio | 9.98 | 9.98 | 3.33 | 5.34 | 5.76 | 6.27 | 6.97 | 13.68 | 1.18 | 7.45 | 0.47 |
| Cash Ratio | 9.82 | 9.82 | 3.10 | 5.00 | 5.45 | 5.83 | 6.61 | 13.36 | 1.03 | 7.19 | 0.25 |
| Asset Turnover | — | 0.12 | 0.02 | — | — | — | 0.02 | — | — | — | — |
| Inventory Turnover | 1.40 | 1.40 | 0.28 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 5.96 | 244.09 | — | — | — | 111.57 | — | — | — | — |
XFOR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
X4 Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.4% | 0.0% | 0.0% | 100.0% | 4.5% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.4% | 0.0% | 0.0% | 100.0% | 4.5% | — |
| Shares Outstanding | — | $42M | $7M | $6M | $2M | $858299 | $669233 | $384333 | $2549 | $1909 | $13235 |
Peer Comparison
Compare XFOR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 XFORYou | $490M | -2.1 | — | — | 82.2% | -247.4% | -76.0% | -143.1% | — |
 CYCN | $14M | -2.9 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARDX | $1B | -22.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 AGEN | $137M | -970.6 | — | — | 29.6% | -18.0% | — | — | — |
 RARE | $2B | -4.1 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 KRYS | $9B | 47.0 | 53.6 | 50.2 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
What if you invested $1,000 in XFOR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in XFOR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs XFOR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationXFOR vs CYCN — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Cyclerion Therapeutics, Inc..
Compare NowXFOR — Frequently Asked Questions
Quick answers to the most common questions about buying XFOR stock.
What is X4 Pharmaceuticals, Inc.'s P/E ratio?
X4 Pharmaceuticals, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
What is X4 Pharmaceuticals, Inc.'s ROE?
X4 Pharmaceuticals, Inc.'s return on equity (ROE) is -76.0%. The historical average is -117.7%.
Is XFOR stock overvalued?
Based on historical data, X4 Pharmaceuticals, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are X4 Pharmaceuticals, Inc.'s profit margins?
X4 Pharmaceuticals, Inc. has 82.2% gross margin and -247.4% operating margin.